Arvinas, INC 8-K filings

Arvinas announced strong Q2 2026 results, highlighted by the FDA approval of VEPPANU, the first PROTAC degrader, and a strategic out-licensing agreement with Rigel Pharmaceuticals.

Arvinas, Inc. successfully concluded its 2026 annual meeting, confirming the election of directors and ratification of its auditor.

Arvinas, Inc. announced the effectiveness of its license agreement with Rigel Pharmaceuticals, Inc. for VEPPANU (vepdegestrant), receiving an initial $70 million payment.

Arvinas, Inc. announced a strategic pipeline re-prioritization, focusing on ARV-806 and planning to seek out-licensing for further development.

Arvinas announced first quarter 2026 financial results, highlighted by the FDA approval of VEPPANU and a corporate update on its pipeline.

Arvinas and Pfizer have entered into a license agreement with Rigel Pharmaceuticals for the exclusive global rights to VEPPANU (vepdegestrant), an ER+ breast cancer treatment.

Arvinas and partner Pfizer have received FDA approval for VEPPANU, the first-ever PROTAC protein degrader, for the treatment of specific advanced breast cancer.

Arvinas, Inc. announced positive Phase 1 clinical trial data for ARV-102, demonstrating over 50% LRRK2 degradation in Parkinson's disease patients and plans for further neurodegenerative disease trials.

Arvinas announced its Q4 and full-year 2025 financial results, highlighting significant pipeline progress and a cash runway into the second half of 2028.

Arvinas, Inc. announced a leadership transition with Randy Teel appointed as President and CEO, succeeding John Houston, who will remain on the Board.

Arvinas, Inc. announced positive preclinical data for its PROTAC BCL6 degrader ARV-393 in combination with glofitamab, demonstrating enhanced tumor growth inhibition and regression in lymphoma models.

Arvinas, a clinical-stage biotechnology company, reported its third-quarter 2025 financial results and provided updates on its PROTAC degrader pipeline, including positive Phase 1 data for ARV-102 and strategic plans for vepdegestrant.

Arvinas, Inc. announced robust preclinical data for its PROTAC KRAS G12D degrader, ARV-806, demonstrating significant tumor growth inhibition and best-in-class potential.

Arvinas announced new patient-reported outcomes data from its Phase 3 VERITAC-2 trial, showing vepdegestrant significantly improved quality of life for breast cancer patients.

Arvinas, Inc. announced positive Phase 1 clinical trial data for its PROTAC LRRK2 degrader, ARV-102, demonstrating safety, brain penetration, and target engagement in healthy volunteers and Parkinson's patients.

Arvinas, Inc. announced a strategic shift to out-license vepdegestrant, reduce its workforce by 15%, and initiate a $100 million share repurchase program, while reaffirming its cash runway into H2 2028.

Arvinas and Pfizer announced the FDA's acceptance of the New Drug Application for vepdegestrant, a PROTAC ER degrader for advanced breast cancer, setting a PDUFA action date of June 5, 2026.

Arvinas, Inc. reported its second quarter 2025 financial results, highlighted by the submission of a New Drug Application for vepdegestrant and significant progress across its PROTAC degrader pipeline.

Arvinas, Inc. announced that John Houston, Ph.D., will retire as President and Chief Executive Officer following the appointment of a successor, but will continue to serve as Chairperson of the Board of Directors.

Arvinas, Inc. reported the resignation of director John Young and the results of its 2025 Annual Meeting, including the election of Class I directors, approval of executive compensation, and ratification of its independent auditor.

Arvinas, Inc. announced encouraging preclinical results for its investigational PROTAC BCL6 degrader, ARV-393, demonstrating significant single-agent activity and enhanced efficacy in combination therapies for various non-Hodgkin lymphoma subtypes.

Arvinas, Inc. announced the retirement of Dr. Ian Taylor, President of Research and Development, effective June 6, 2025, who will transition to a one-year consulting agreement.

Arvinas, in collaboration with Pfizer, has submitted a New Drug Application to the U.S. FDA for vepdegestrant, a PROTAC ER degrader, for the treatment of ESR1-mutated ER+/HER2advanced or metastatic breast cancer.

Arvinas, Inc. and Pfizer, Inc. have unveiled detailed positive results from the Phase 3 VERITAC-2 clinical trial, demonstrating vepdegestrant's significant improvement in progression-free survival for patients with ESR1-mutant, ER+/HER2advanced breast cancer.

Arvinas announces positive results from its Phase 3 VERITAC-2 trial, a corporate restructuring including a workforce reduction, and an updated cash runway into the second half of 2028.

Arvinas' ARV-393, a PROTAC BCL6 degrader, shows synergistic antitumor activity in preclinical studies when combined with standard-of-care and investigational therapies for B-cell lymphoma.

Arvinas announced positive first-in-human clinical trial data for ARV-102, an investigational PROTAC LRRK2 degrader, demonstrating blood-brain barrier penetration and substantial LRRK2 reduction in healthy volunteers.

Arvinas and Pfizer report positive topline results from the Phase 3 VERITAC-2 trial of vepdegestrant, demonstrating statistically significant improvement in progression-free survival in patients with estrogen receptor 1-mutant advanced or metastatic breast cancer.

Arvinas announces anticipated topline data from the Phase 3 VERITAC-2 trial in Q1 2025 and reports financial results for Q4 and full year 2024, highlighting progress across its pipeline.

Arvinas, Inc. has terminated its lease for office space in New Haven, Connecticut, effective December 31, 2024.